Wijaya YOS,Nishio H,Niba ETE,Okamoto K,Shintaku H,Takeshima Y,Saito T,Shinohara M,Awano H
Spinal muscular atrophy (SMA) is a lower motor neuron disease, once considered incurable. The main symptoms are muscle weakness and muscular atrophy. More than 90% of cases of SMA are caused by homozygous deletion of survival motor neuron 1 (). Emerging treatments, such as splicing modulation of and gene replacement therapy, have improved the prognoses and motor functions of patients. However, confirmed diagnosis by testing is often delayed, suggesting the presence of diagnosis-delayed or undiagnosed cases. To enable patients to access the right treatments, a screening system for SMA is essential. Even so, the current newborn screening system using dried blood spots is still invasive and cumbersome. Here, we developed a completely non-invasive screening system using dried saliva spots (DSS) as an alternative DNA source to detect deletion. In this study, 60 DSS (40 SMA patients and 20 controls) were tested. The combination of modified competitive oligonucleotide priming-polymerase chain reaction and melting peak analysis clearly distinguished DSS samples with and without . In conclusion, these results suggest that our system with DSS is applicable to SMA patient detection in the real world.
Department of Community Medicine and Social Healthcare Science, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Hyogo, Japan.
10.3390/genes12101621 read more